Table 1.

Patient characteristics for eligible patients (Part A and B, N = 85)

Characteristic	Number (%) (Part A) N=13	Number (%) (Part B) N=72	Number (%) (All) N=85
Age (years)
Median	10	15	14
Range	5 – 15	1 – 27	1 – 27
Sex
Male	7 (54)	44 (61)	51 (60)
Female	6 (46)	28 (39)	34 (40)
Race
White	13 (100)	51 (71)	64 (75)
Asian	0 (0)	5 (7)	5 (6)
American Indian or Alaska Native	0 (0)	0 (0)	0 (0)
Black or African American	0 (0)	8 (11)	8 (10)
Multiple Races	0 (0)	2 (3)	2 (2)
Unknown	0 (0)	6 (8)	6 (7)
Ethnicity
Non-Hispanic	10 (77)	60 (83)	70 (82)
Hispanic	3 (13)	10 (14)	13 (15)
Unknown	0 (0)	2 (3)	2 (2)
Diagnosis
Epithelioid sarcoma	2 (15.4)		2 (2.4)
Ewing sarcoma	1 (7.7)	10 (13.9)	11 (12.9)
Hodgkin lymphoma		12 (16.7)	12 (14.2)
Non-Hodgkin lymphoma
Diffuse large B-cell		3 (4.2)	3 (3.5)
Non-Hodgkin, NOS		1 (1.4)	1 (1.2)
Burkitt lymphoma		3 (4.2)	3 (3.5)
Mediastinal large B-cell lymphoma		3 (4.2)	3 (3.5)
Melanoma		1 (1.4)	1 (1.2)
Neuroblastoma, NOS	4 (30.8)	18 (25)*	22 (25.9)
Osteosarcoma, NOS	3 (23.1)	10 (13.9)	13 (15.3)
Rhabdomyosarcoma, NOS	1 (7.7)	11 (15.3)	12 (14.2)
Sarcoma, NOS	1 (7.7)		1 (1.2)
Undifferentiated sarcoma	1 (7.7)		1 (1.2)
Prior Therapy
Chemotherapy Regimens	N=13	N=71	N=84
Median	2	3	2.5
Range	1–6	1–16	1–16
Radiation Therapy	N=10	N=46	N=56
Median	1	1	1
Range	1–3	1–5	1–5

^*Cohort B1(neuroblastoma measurable disease) and Cohort B8 (neuroblastoma detectable by MIBG only) patients are combined in this table.